SCYX Stock Price
SCYNEXIS, Inc.
SCYX stock price is $3.50 (+6.06% on the day), giving SCYNEXIS, Inc. a market cap of $34.84M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
SCYX Stock Overview
- Price
- $3.50
- Previous close
- $3.30
- Open
- $3.34
- Market cap
- $34.84M
- P/E ratio
- -4.0
- 52-week range
- $3.28 - $9.12
- 1-year price target
- $36.33
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NSC
- MarketXLS Rank
- 44
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SCYX | $3.50 | +6.1% | 24.71K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |